TAMPA, Fla.–(BUSINESS WIRE)– #DED–Verséa™ Ophthalmics, LLC, a division of Verséa Health, Inc. committed to delivering novel, high-value diagnostic and therapeutic solutions to improve ocular disease, proudly announces the commencement of initial shi…
Author: Business Wire
Marsai Martin and GlassesUSA.com Inspire a New Generation of Glasses Wearers in New “Four Eyes Are Better Than Two” Campaign
NEW YORK CITY–(BUSINESS WIRE)–GlassesUSA.com, the leading online eyewear retailer in the United States, today announced the launch of a specially curated eyewear collection in collaboration with BET award winner, and industry trailblazer, Marsai Mart…
LENSAR® Reports Adoption of ALLY® System in Multi-Center Ophthalmology Groups
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that it has completed …
North Carolina Association of Free and Charitable Clinics Expects Surge in Patients as 'Unwinding' Puts Medicaid Benefits at Risk for at Least 300,000
WINSTON-SALEM, N.C.–(BUSINESS WIRE)–North Carolina’s nonprofit free and charitable clinics that provide low-cost/no-cost health care to the uninsured are expecting an influx of new patients as more than 300,000 people face losing their Medicaid cover…
National Vision Awards $7,000 in Scholarships to National Optometric Student Association Members and Receives Founder’s Award at 2023 Convention
DULUTH, Ga.–(BUSINESS WIRE)–National Vision, Inc., the nation’s second largest optical retailer providing quality, affordable eye care and eyewear, announced the winners of its 2023 National Optometric Student Association (NOSA) scholarships, awardin…
New Clinical and Real-World Data for Genentech’s Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that data from its ophthalmology portfolio will be highlighted in 25 abstracts at the 2023 American Society of Retina Spe…
EyeCare Partners Appoints Daniel Miller, M.D., Ph.D., as Executive Medical Officer
ST. LOUIS–(BUSINESS WIRE)–EyeCare Partners appoints Daniel Miller, M.D., Ph.D., as Executive Medical Officer.
Aviceda Announces Podium Presentations on AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of Geographic Atrophy from Macular Degeneration, at American Society of Retina Specialists (ASRS) and the OIS Retina Innovation Summit Meetings
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics, a private late clinical-stage biotech company focused on developing next generation immuno-modulators by harnessing the power of glycobiology to alleviate chronic non-resolving inflammation, anno…
Harrow Prices $60 Million Public Offering of Common Stock
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it priced an underwritten registered public offering of 3,380,282 shares of its common stock at a price of $17.75 pe…
STAAR Surgical to Report Second Quarter Results on August 2, 2023
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the second quarter ended June 30, …
Harrow erwirbt US-amerikanische und kanadische Vermarktungsrechte für VEVYE® (Cyclosporin-Augenlösung) 0,1 % von Novaliq
NASHVILLE, Tenn. & HEIDELBERG, Deutschland–(BUSINESS WIRE)–Harrow (Nasdaq: HROW), ein führendes US-amerikanisches Unternehmen im Bereich der Augenheilkunde, und die Novaliq GmbH, ein deutsches biopharmazeutisches Unternehmen, das sich auf erstklassig…
Santen s’engage dans des accords de licence et de transfert d’actifs pour ses produits pharmaceutiques en Amérique du Nord
OSAKA, Japon–(BUSINESS WIRE)–Santen Pharmaceutical Co. (ci-après Santen) a annoncé aujourd’hui la signature d’accords de licence et de transfert d’actifs avec deux sociétés américaines. Santen a conclu un accord de licence avec Visiox Pharmaceuticals…
Harrow Acquires Santen’s Branded Ophthalmic Portfolio
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of agreements with affiliates of Santen Pharmaceutical Co., Ltd. (“Santen”) under which Harrow will acquire c…
Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America
OSAKA, Japan–(BUSINESS WIRE)–Santen Pharmaceutical Co., Ltd. (hereafter Santen) announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies. Santen has come to an out-licensing agreement with Visiox…
Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance
NASHVILLE–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the following select preliminary second quarter 2023 financial guidance: Second quarter 2023 revenues in excess of $31.0 million…
Harrow Announces Proposed Public Offering of Common Stock
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced a proposed underwritten registered public offering of its common stock, subject to market and certain other conditions. H…
Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq
NASHVILLE, Tenn. & HEIDELBERG, Germany–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Novaliq GmbH, a German biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, toda…
Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects
LOS ANGELES–(BUSINESS WIRE)—- $CDXC #ARVO–ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+), announced promising findings from two independent clinical study abstracts originally presented this past Apr…
ForSight Robotics Expands Leadership Team with Appointment of CFO
YOKNEAM ILLIT, Israel–(BUSINESS WIRE)– #CFO–ForSight Robotics, pioneer of robotic eye surgery, appoints seasoned medical device executive Sharon Levita as Chief Financial Officer (CFO).
OcuTerra Completes Enrollment in Phase 2 DR:EAM Clinical Trial of Topically Delivered OTT166 in Adults with Diabetic Retinopathy
BOSTON–(BUSINESS WIRE)–OcuTerra Therapeutics announces full enrollment for its Phase 2 clinical trial of OTT166.